GlassScriptPhysician profile
Joseph P Puente
NPI 1356312730
$4,846.26
in general payments reported to CMS, 2019-2025
23 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $881 · 2021: $886 · 2022: $692 · 2023: $536 · 2024: $462 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.36 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $724.84 | 2019-2023 | |
| Lilly USA, LLC | $711.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $514.51 | 2019-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $418.07 | 2019-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $300.94 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.73 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $182.34 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.76 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $157.31 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $87.43 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.92 | 2020-2023 | Seglentis |
| Amgen INC. | $81.71 | 2020-2022 | |
| Pfizer INC. | $60.50 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $59.87 | 2019-2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.14 | 2021-2022 | |
| Esperion Therapeutics, INC. | $39.16 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $38.99 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $34.91 | 2025 | Voquezna |
| Mylan Specialty L.P. | $20.12 | 2020 | |
| Abbott Laboratories | $17.28 | 2021 | |
| Tris Pharma INC | $12.78 | 2023 | Dyanavel Xr |
| Horizon Therapeutics Plc | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.